东诚药业(002675.SZ)：下属公司获得药物临床试验批准通知书

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary LNC PHARMA PTE. LTD. received FDA approval for the clinical trial of 225Ac-LNC1011 injection, with Phase I trials to commence shortly [1] Group 1 - The FDA issued a Study May Proceed Letter (SMP) for the clinical trial of 225Ac-LNC1011 injection [1] - The clinical trial is set to begin in the near future [1]